I was not planning to write a new post for several more days, but there have been two important developments that I thought were worth discussing separately from my upcoming “brief items of interest” once a month post. I will update this post in more detail later if necessary (1:30 am here right now!), but for now, here are the main developments so as to let people comment about them here rather in my prior blog post on Dr. Tsuji.
- First, Histogen has finally published a summary of its presentation at the recent Stem Cell Summit in Boston that I discussed in my last “brief items of interest post” from April. After reading blog reader “Sam”‘s comment in the last post that he got a response from Histogen, I also e-mailed them. They sent me a pdf of their presentation that was made by CEO Dr. Gail Naughton: Histogen’s Presentation at the 5th Stem Cell Product Development and Commercialization Conference in Boston on April 27th, 2016.
- Second, if you recall, a month ago I wrote a post on Follica’s surprising return from being taken as almost dead by many people. That post happened due to HLT forum member Xaser94’s great research, which he outlined in his now very popular thread. Several days ago, forum member “Noisette” made an interesting post in that same thread (see page 8) with a link to a 271 page prospectus document from PureTech Health (majority owner of Follica) from June 2015. There is a goldmine of information in there with some superb images. The main Follica section starts on page 101. Encouraging quote: “Through the administration of Follica’s procedure by a trained clinician and use of its at home ‘‘connected’’ device (meaning it is coupled with a digital service such as a companion smart- phone application) the company seeks, in the near-term, to significantly improve the treatment expectations and satisfaction of hair loss patients by providing a more effective alternative to current FDA-approved drugs.“
I also want to give kudos to Mike, who e-mailed me some useful information on this development (this is the same Mike that I discussed in my Follica post from a month ago). This time, I will only paste part of Mike’s e-mail:
“This section stands out – and there are many standouts –
Follica’s patented platform employs a technique called targeted cutaneous perturbation (or TCP) to stimulate the growth of new follicles, followed by treatment with: (i) select, approved drugs indicated to be synergistic in maximising the quantity, quality and persistence of new hair, or in other cases (ii) new chemical entities that modulate pathways involved in the development of the hair follicle.
It’s the new chemical entities that interests me – could there be a treatment and then an upgrade treatment further down the line. A partnership with another company perhaps – maybe one that’s related to a certain Neal Walker?”
In seems like in the past month, most of my posts have been heavily influenced by commentators on this blog, e-mailers, hair loss forum posters and even one hair loss chat participant on this site! The last mentioned is surprising, since most of the chat page on this site often gets filled with garbage that I have to delete, or gets filled with childish but somewhat relevant messages pertaining to hair loss. I am considering upgrading the chat via paying for a plugin that might require logins, but am not sure yet.